Get the Stockscreener App
9.70
0.10%
-0.01
Pre-market:
9.70
Xeris Biopharma Holdings Inc stock is traded at $9.70, with a volume of 1.92M.
It is down -0.10% in the last 24 hours and up +19.16% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$9.71
Open:
$9.76
24h Volume:
1.92M
Relative Volume:
0.76
Market Cap:
$1.57B
Revenue:
$246.03M
Net Income/Loss:
$-32.00M
P/E Ratio:
-45.65
EPS:
-0.2125
Net Cash Flow:
$-16.78M
1W Performance:
+5.32%
1M Performance:
+19.16%
6M Performance:
+112.25%
1Y Performance:
+201.24%
1-Day Range:
$9.57
$9.97
1-Week Range:
$9.11
$10.03
52-Week Range:
$2.82
$10.03
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
9.70 | 1.57B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Applying chart zones and confluence areas to Xeris Biopharma Holdings Inc.2025 Trade Ideas & Fast Exit and Entry Trade Guides - newser.com
Xeris Biopharma (NASDAQ:XERS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Y Intercept Hong Kong Ltd Acquires 291,696 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is a relief rally coming for Xeris Biopharma Holdings Inc. holdersEarnings Summary Report & AI Driven Price Predictions - newser.com
What high frequency data says about Xeris Biopharma Holdings Inc.2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsGlobal Markets & Weekly Return Optimization Alerts - newser.com
Xeris Biopharma Hits New 52-Week High of $10.03, Up 314.66% - Markets Mojo
Can Xeris Biopharma Holdings Inc. stock maintain operating marginsWeekly Gains Summary & Growth Focused Stock Reports - newser.com
Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com
Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsWeekly Investment Report & Fast Moving Trade Plans - newser.com
Using R and stats models for Xeris Biopharma Holdings Inc. forecasting2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is Xeris Biopharma Holdings Inc. stock undervalued vs historical averagesWeekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Can Xeris Biopharma Holdings Inc. stock maintain growth trajectoryJuly 2025 Outlook & Long-Term Investment Growth Plans - newser.com
How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.July 2025 Movers & Community Verified Swing Trade Signals - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winner2025 Price Action Summary & Fast Entry and Exit Trade Plans - newser.com
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.Market Activity Recap & Accurate Technical Buy Alerts - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendationsQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Hits New 1-Year HighStill a Buy? - MarketBeat
Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentals2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Xeris Biopharma Hits New 52-Week High of $9.48, Up 297% Year-Over-Year - Markets Mojo
Oppenheimer Adjusts Price Target on Xeris Biopharma to $18 From $8, Maintains Outperform Rating - MarketScreener
What Xeris Biopharma Holdings (XERS)'s Strong Revenue Growth and Pipeline Advances Mean For Shareholders - simplywall.st
How Phase 3 XP-8121 Progress at Xeris Biopharma Holdings (XERS) Has Changed Its Investment Story - Yahoo Finance
Is Xeris Biopharma Holdings Inc a good long term investmentDividend Stock Watch & Superior Trading Portfolio - earlytimes.in
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):